2017 American Society of Clinical Oncology Annual Meeting

2017 American Society of Clinical Oncology Annual Meeting

Olaparib Is First PARP Inhibitor to Show Advantage in BRCA-Mutated Breast Cancer

The PARP inhibitor olaparib significantly improved progression-free survival (PFS) compared with standard chemotherapy in women with HER2-negative metastatic breast cancer with a germline BRCA mutation. Disease progression was delayed by [ Read More ]

2017 American Society of Clinical Oncology Annual Meeting

Alectinib a New Standard of Care for ALK-Positive NSCLC

Alectinib, a next-generation ALK inhibitor, was called a new standard of care for ALK-positive non–small cell lung cancer (NSCLC) based on results from the phase 3 ALEX clinical trial presented [ Read More ]

2017 American Society of Clinical Oncology Annual Meeting

Pembrolizumab Makes Inroads in Sarcoma Subtypes

The number of tumor types amenable to pembroliz­umab immunotherapy keeps expanding and now includes sarcoma, which has been difficult to treat. In the SARC028 phase 2 multicenter trial, reported at [ Read More ]

2017 American Society of Clinical Oncology Annual Meeting

Promising Survival Signal with Cediranib as Combination in Relapsed Ovarian Cancer

Oral cediranib, an investigational VEGF inhibitor, in combination with a PARP or chemotherapy inhibitor, appears to have a survival benefit in women with relapsed platinum-sensitive ovarian cancer, according to data [ Read More ]